Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide

Immunology

Volumn 119, Issue 3, 2006, Pages 306-316

  Lazoura, Eliada ^a   Lodding, Jodie ^a   Farrugia, William ^a   Ramsland, Paul A ^a   Stevens, James ^b   Wilson, Ian A ^b   Pietersz, Geoffrey A ^a   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anchor modifications; H 2Kb; Mucin 1; Mucin 1 8; Non canonical peptide; Vaccine design

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; MUCIN [1-8]; OVALBUMIN; PROTEIN; PROTEIN H 2K; SERYLALANYLPROLYLASPARTYLPHENYLALANYLARGINYLPROLYLLYSINE; SERYLALANYLPROLYLASPARTYLTHREONYLARGINYLPROLYLALANINE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN STRUCTURE;

ANIMALS; ANTIGENS, NEOPLASM; CA-15-3 ANTIGEN; CANCER VACCINES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DROSOPHILA MELANOGASTER; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, MOLECULAR; MUCIN-1; MUTATION; PEPTIDE FRAGMENTS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTE SUBSETS;

EID: 33750001550     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02434.x     Document Type: Article

References (50)

1. Pietersz GA, Apostolopoulos V, McKenzie IF. Generation of cellular immune responses to antigenic tumor peptides. Cell Mol Life Sci 2000; 57:290-310.
2. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E, Kourilsky P. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 1992; 89:416-20.
3. Fedoseyeva EV, Boisgerault F, Anosova NG, Wollish WS, Arlotta P, Jensen PE, Ono SJ, Benichou G. CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol 2000; 164:5641-51.
4. McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol Immunother 2000; 49:417-25.
5. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185:833-41.
6. Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997; 186:695-704.
7. Andersen ML, Ruhwald M, Nissen MH, Buus S, Claesson MH. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol 2003; 57:21-7.
8. Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol 1997; 27:2579-87.
9. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 1997; 159:5211-18.
10. Apostolopoulos V, Lazoura E. Noncanonical peptides in complex with MHC class I. Expert Rev Vaccines 2004; 3:151-62.
11. Apostolopoulos V, Matsoukas J, Plebanski M, Mavromoustakos T. Applications of peptide mimetics in cancer. Curr Med Chem 2002; 9:411-20.
12. Apostolopoulos V, McKenzie IF, Wilson IA. Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design. Front Biosci 2001; 6:D1311-20.
13. Apostolopoulos V, Yu M, Corper AL, Li W, McKenzie IF, Teyton L, Wilson IA, Plebanski M. Crystal structure of a non-canonical high affinity peptide complexed with MHC class I. A novel use of alternative anchors. J Mol Biol 2002; 318:1307-16.
14. Apostolopoulos V, Yu M, Corper AL, Teyton L, Pietersz GA, McKenzie IF, Wilson IA, Plebanski M. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I. A new approach for vaccine design. J Mol Biol 2002; 318:1293-305.
15. Apostolopoulos V, Yu M, McKenzie IF, Wilson IA. Structural implications for the design of molecular vaccines. Curr Opin Mol Ther 2000; 2:29-36.
16. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003; 100:15029-34.
17. Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 2005; 12:629-39.
18. Lazoura E, Apostolopoulos V. Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem 2005; 12:1481-94.
19. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153:5586-92.
20. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156:3308-14.
21. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI. database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-19.
22. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995; 7:85-96.
23. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41:178-228.
24. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 2000; 12:251-61.
25. Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992; 257:919-27.
26. Fremont DH, Stura EA, Matsumura M, Peterson PA, Wilson IA. Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc Natl Acad Sci USA 1995; 92:2479-83.
27. Gao L, Walter J, Travers P, Stauss H, Chain BM. Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope. J Immunol 1995; 155:5519-26.
28. Ostrov DA, Roden MM, Shi W et al. How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination. J Immunol 2002; 168:283-9.
29. Jackson MR, Song ES, Yang Y, Peterson PA. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci USA 1992; 89:12117-21.
30. Saito Y, Peterson PA, Matsumura M. Quantitation of peptide anchor residue contributions to class I major histocompatibility complex molecule binding. J Biol Chem 1993; 268:21309-17.
31. Stura EA, Matsumura M, Fremont DH, Saito Y, Peterson PA, Wilson IA. Crystallization of murine major histocompatibility complex class I H-2Kb with single peptides. J Mol Biol 1992; 228:975-82.
32. Matsumura M, Saito Y, Jackson MR, Song ES, Peterson PA. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J Biol Chem 1992; 267:23589-95.
33. Apostolopoulos V, Pouniotis DS, van Maanen PJ et al. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine 2006; 24:3191-202.
34. Pouniotis DS, Apostolopoulos V, Pietersz GA. Penetratin tandemly linked to a CTL peptide induces anti-tumor T cell responses via a cross-presentation pathway. Immunol 2006; 117:329-39.
35. Pouniotis DS, Proudfoot O, Bogdanoska V, Apostolopoulos V, Fifis T, Plebanski M. Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun 2004; 72:5331-9.
36. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Meth Enzymol 1997; 276:307-17.
37. Roussel A, Cambillau C. TURBO-FRODO molecular graphics program. Mountain View, CA: Silicon Graphics Partner Directory, Silicon Graphics, 1989: 77-87.
38. Brunger AT, Adams PD, Clore GM et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54(5):905-21.
39. Laskowski RA, Moss DS, Thornton JM. Main-chain bond lengths and bond angles in protein structures. J Mol Biol 1993; 231:1049-67.
40. Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, Hill AV. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997; 15:1280-4.
41. Lee EA, Palmer DR, Flanagan KL et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002; 70:1417-21.
42. Plebanski M, Burtles SS. In vitro primary responses of human T cells to soluble protein antigens. J Immunol Meth 1994; 170:15-25.
43. Plebanski M, Flanagan KL, Lee EA et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 1999; 10:651-60.
44. Plebanski M, Gilbert SC, Schneider J et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998; 28:4345-55.
45. Pietersz GA, Li W, Popovski V, Caruana JA, Apostolopoulos V, McKenzie IF. Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunol Immunother 1998; 45:321-6.
46. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14:178-82.
47. Gross DA, Graff-Dubois S, Opolon P et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113:425-33.
48. Bredenbeck A, Losch FO, Sharav T et al. Identification of non-canonical melanoma-associated T cell epitopes for cancer immunotherapy. J Immunol 2005; 174:6716-24.
49. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000; 30:3411-21.
50. Tirosh B, el-Shami K, Vaisman N et al. Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunol Lett 1999; 70:21-8.